title: Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.
abstract: Twenty-seven HIV-1-infected patients, 16 at early stage of disease and without concomitant antiretroviral therapy and 11 at more advanced stage of disease receiving antiretroviral therapy, have been followed since their enrollment, November 1992 and July 1993, respectively, in phase I/II studies to evaluate safety and immunogenicity of an anti-interferon-alpha (IFN-alpha) vaccine, aimed at modulating the impaired cytokine network in AIDS patients by counteracting IFN-alpha overproduction. We compared clinical, virological, and immunological markers of disease progression, including circulating IFN-alpha levels in a 24- to 30-month follow-up period with those of 62 patients fulfilling the same enrollment criteria and comparable for sex, risk factor, and age, regularly followed at our center. Anti-IFN-alpha immunization consisted of four-six intramuscular injections 1 month apart of a water-in-oil emulsion of 500 micrograms formalin-inactivated recombinant IFN-alpha-2b (iIFN-alpha) followed by intramuscular injections of 250 micrograms iIFN-alpha adsorbed onto calcium phosphate every 3 months. Neither clinical deterioration nor a CD4+ cell count decrease from pretreatment values was observed in IFN-alpha-immunized patients in the follow-up period, whereas clinical and immunological disease progressions were observed among open-comparison patients. Furthermore, statistical analysis showed a strong association between occurrence of clinical manifestations and high circulating IFN-alpha titers, while nonprogression of IFN-alpha-immunized patients was associated with decreased levels of circulating IFN-alpha.
authors.affiliation: A. Bianchi Bonomi Hemophilia & Thrombosis Center, IRCCS Maggiore Hospital, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Gringeri
authors.forename: E
authors.initials: E
authors.lastname: Santagostino
authors.forename: M
authors.initials: M
authors.lastname: Cusini
authors.forename: M
authors.initials: M
authors.lastname: Muça-Perja
authors.forename: A
authors.initials: A
authors.lastname: Marinoni
authors.forename: P M
authors.initials: PM
authors.lastname: Mannucci
authors.forename: A
authors.initials: A
authors.lastname: Burny
authors.forename: M
authors.initials: M
authors.lastname: Criscuolo
authors.forename: W
authors.initials: W
authors.lastname: Lu
authors.forename: J M
authors.initials: JM
authors.lastname: Andrieru
authors.forename: J P
authors.initials: JP
authors.lastname: Mbika
authors.forename: A
authors.initials: A
authors.lastname: Lachgar
authors.forename: L S
authors.initials: LS
authors.lastname: Fall
authors.forename: V
authors.initials: V
authors.lastname: Chams
authors.forename: M
authors.initials: M
authors.lastname: Feldman
authors.forename: P
authors.initials: P
authors.lastname: Hermans
authors.forename: J F
authors.initials: JF
authors.lastname: Zagury
authors.forename: B
authors.initials: B
authors.lastname: Bizzini
authors.forename: M
authors.initials: M
authors.lastname: Musicco
authors.forename: D
authors.initials: D
authors.lastname: Zagury
mesh_terms: D000293:Adolescent; D000328:Adult; D018791:CD4 Lymphocyte Count; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D016655:HIV Core Protein p24 / Q000032:analysis; D015658:HIV Infections / Q000628:therapy* / Q000821:virology; D015497:HIV-1; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D016898:Interferon-alpha / Q000032:analysis / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D014611:Vaccination
chemical_list: D016655:HIV Core Protein p24; D016898:Interferon-alpha